Leucémies

ZITTOUN R, VARET B. Leucémies aiguës. Progrès en hématologie, vol. 10, Paris, Doin, 1989.

ANDREU G, BENBUNAN M, BOASSON M et coll. Pratiques transfusionnelles en hématologie clinique. Recommandations de la Commission d’Évaluation du Collège Français des Hématologistes pour le support transfusionnel dans le traitement des leucémies aiguës en aplasie thérapeutique. Nouv Rev Fr Hémat, 1993, 35 : 517-524.

CORDONNIER C, SCHLEMMER B, LEVERGER G et coll. Stratégie antibiotique dans les épisodes fébriles au cours des neutropénies profondes (inférieures à 500 PNN) et prolongées (supérieures ou égales à 7 jours). Nouv Rev Fr Hémat, 1994, 34 : 289-291

PRETI A, KARTARJIAN H. Management of adult lymphoblastic leukemia : present issues and key challenges. J Clin Oncol, 1994, 12 : 1312-1322

BISHOP JF. Intensified therapy for acute myeloid leukemia. N Engl J Med, 1994, 331 : 941-942

MAYER RJ, DAVS RB, SCHIFFER CA et al. Intensive post remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med, 1994, 331 : 891-903

FENAUX P, LE MELEY M, CASTAIGNE S et al. Effect of all-transretinoid acid in newly diagnosed acute promyelocytic leukemia. Blood, 1993, 82 : 3241-3249

DIGHIERO G, TRAVADE PH, CHEVRET S et al. B cell chronic lymphocytic leukemia. Present status and future directions. Blood, 1991, 78 : 1901-1914

FRENCH COOPERATIVE GROUP ON CHRONIC LYMPHOCYTIC LEUKEMIA. Natural history of stage. A chronic lymphocytic leukemia untreated patients. Br J Haematol, 1990, 32 : 327-331

ROZMAN C. Chronic lymphocytic leukemia and related disorders. Baillère’s Clin Haematol, 1993, 69 (4) : 757-885

TANZER J. Leucémie myéloïde chronique (LMC). Biologie moléculaire. Nouv Rev Fr Hématol, 1993, 35 : 155-160

KURZROCK R, TALPAZ M. The molecular pathology of chronic myeloid leukemia. Br J Haematol, 1991, 79 (Suppl. 1) : 34-37

DALEY GQ, VAN ETTEN RA, BALTIMORE D. Induction of chronic myelogenous leukemia by the P210 bcr/abl gene of the Philadelphia chromosome. Science, 1990, 247 : 824-829

GUILHOT F. Le traitement de la leucémie myéloïde chronique. Nouv Rev Fr Hématol, 1993, 35 : 151-154

LEBEAU MM, VARDIMAN JW. Laboratory evaluation of chronic myeloid leukemia. In : RL Bick. Hematology. Clinical and laboratory practice, St-Louis, Mosby, 1993 : 1225-1238

MARTIAT P, MICHAUX JL, RODHAIN J et al. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML) : comparison with Ph+ CML and chronic myelomonocytic leukemia. Blood, 1991, 78 : 205-211

KANTARJIAN HM, KEATING MJ, TALPAZ M et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med, 1987, 83 : 445-454

SOKAL JE. Prognosis in chronic myeloid leukemia : biology of the disease vs treatment. Baillere’s Clin Haematol, 1987, 1 : 907-929

SAVAGE DG, GOLDMAN JM. Approches to the treatment of chronic myeloid leukemia. Intern J Hematol, 1994, 60 : 1-21

HEHLMANN R, HEIMPEL H, HASFORD J et al. Randomized comparison of busulfan and hydroxyurea in chronic myeloid leukemia : prolongation of survival by hydroxyurea. Blood, 1993, 82 : 398-407

THE ITALIAN COOPERATIVE STUDY GROUP ON CHRONIC MYELOID LEUKEMIA. Interferon alfa-2 as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med, 1994, 330 : 820-825

CLIFT RA, APPELBAUM FR, THOMAS ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood, 1993, 82 : 1954-1956

Lymphomes malins non hodgkiniens

KORSMEYER SJ. Antigen receptor genes as molecular markers of lymphoid neoplasms. J Clin Invest, 1987, 79 : 1291-1296

LENNERT K, MOHRI N, KAISERLING E et al. Malignant lymphomas other than Hodgkin’s disease. Berlin, Heidelberg, New-york, Springer-Verlag, 1978

NATIONAL CANCER INSTITUTE. Sponsored study of classifications of non-Hodgkin’s lymphomas. Summary ans description of a working formulation for clinical usage. Cancer, 1982, 49 : 2112-2135

STEIN H, GERDES J, MASON DY. The normal and malignant germinal center. Clin Haematol, 1992, 11 : 531-559

FOON KA, TOOD RF. Immunologic classification of leukemia and lymphoma. Blood, 1986, 68 : 1-31

HANTO DW, FRIZZERA G, GAJL-PECZALSKA KJ, SIMMONS R. Epstein-Barr virus immunodeficiency and B-cell lymphoproliferation. Transplantation, 1985, 39 : 461-472

HAMILTON-DUTOIT SJ, RAPHAEL M, AUDOUIN J et al. I situ demonstration of Epstein-Barr virus small RNAs (EBER1) in acquired immunodeficiency syndrome-related lymphomas : correaltion with tumor morphology and primary site. Blood, 1993, 82 : 619-624

KORSMEYER SJ. Antigen receptor genes as molecular markers of lymphoid neoplasms. J Clin Invest, 1987, 79 : 1291-1296

RAPPAPORT H. Tumors of the hematopoietic system. In : Atlas of the tumor pathology. Section III, Fasc 8. Washington DC, US Forces Institute of Pathology, 1966 : 97-161

LENNERT K, MOHRI N, KAISERLING E et al. Malignant lymphomas other than Hodgkin’s disease. Berlin, Heidelberg, New-york, Springer-Verlag, 1978

DORFMAN RF. Classification of non-Hodgkin’s lymphoma. Lancet, 1974, 1 : 1295-1296

LUKES RJ, COLLINS RD. Immunologic characterization of human malignant lymphomas. Cancer, 1974, 34 : 1488-1503

NATIONAL CANCER INSTITUTE. Sponsored study of classifications of non-Hodgkin’s lymphomas. Summary ans description of a working formulation for clinical usage. Cancer, 1982, 49 : 2112-2135

STANSFELD AG, DIEBOLD J, KAPANCY Y et al. Updated Kiel classification for lymphomas. Lancet, 1988, 1 : 292-293

PHILIP T. Burkitt’s lymphoma in Europe. In : G Lenoir, G O’Connor, CLM Olwency. Burkitt’s lymphoma, Oxford, IARC Scientific Publications Oxford Press, 1985 : 107-118

NATHWANI BN, KIM H, RAPPAPORT H. Malignant lymphoma, lymphoblastic. Cancer, 1976, 38 : 964-983

WEISENBURGER DD, CHAN WC. Lymphomas of follicles. Mantle and follicle center cell lymphomas. Am J clin Pathol, 1993, 99 : 409-420.

SHIN SS, SHEIBANI K. Monocytoid B-cell lymphoma. Am J Clin Pathol, 1993, 99 : 421-425

SALHANY KE, PIETRA GG. Extra-nodal lymphoid disorders. Am J Clin Pathol, 1993, 99 : 472-485

WOTHERSPOON AC, DOGLIONO C, DISS TC et al. Regression of primary low grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 1993, 342 : 575-577

HARRIS NL. Extranodal lymphoid infiltrates and mucosa-associated lymphoid tissue (MALT). A unifying concept. Am J Surg Pathol, 1991, 15 : 879-884

ISAACSON PG. Lymphomas of mucosa-associated lymphoid tissue (MALT). Histopathology, 1990, 16 : 617-619

KUEFFLER PR, BUNN PA. Adult T cell leukemia/lymphoma. Clin haematol, 1986, 15 : 695-720

WINBERG CD. Peripheral T-cell lymphoma. Morphologic and immunologic observations. Am J Clin Pathol, 1993, 99 : 426-435

YAMAGUCHI K, TAKATSUKI K. Adult T cell leukemia-lymphomas. Baillière’s Clin Haematol, 1993, 6 : 899-915

HENNI T, GAULARD P, DIVINE M et al. Comparaison of genetic probe with immunophenotypic analysis in lymphoproliferative disorders : a study of 87 cases. Blood, 1988, 72 : 1937-1963

TONINAI K, MINATO K, OHTSU T et al. Clinicopathologic, immunophenotypic and immunogenotypic analysis of immunoblastic lymphadenopathy like T-cell lymphoma. Blood, 1988, 72 : 1000-1006

STEINBERG AD, SELDIN MF, JAFFE ES et al. Angioimmunoblastic lymphadenopathy with dysproteinemia. Ann Intern Med, 1988, 108 : 574-584

SPIER CM, LIPPMAN SM, MILLER TP et al. Lennert’s lymphoma. A clinicopathologic study with emphasis on phenotype and its relation to survival. Cancer, 1988, 61 : 517-524

GAULARD P, HENNI T, MAROLLEAU JP et al. Lethal midline granuloma (polymorphic reticulosis) and lymphomatoid granulomatosis : evidence for a monoclonal T-cell lymphoproliferative disorder. Cancer, 1988, 62 : 705-710

LIPFORD EH, MARGOLICK JB, LONGO DL et al. Angiocentric immunoproliferative lesions : a clinico-pathologic spectrum of post-thymic T-cell proliferations. Blood, 1988, 72 : 1674-1681

HORNING SJ. Natural history and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol, 1993, 20 : 75-88

HANTO DW, FRIZZERA G, GAJL-PECZALSKA KJ, SIMMONS R. Epstein-Barr virus immunodeficiency and B-cell lymphoproliferation. Transplantation, 1985, 39 : 461-472

LOCKER J, NALESNIK M. Molecular genetic analysis of lymphoid tumor arising after organ transplantation. Am J Pathol, 1989, 135 : 977-987

RAPHAEL M, GENTILHOMME O, TULLIEZ M et al. Histopathologic features of the high grade non-Hodgkin’s lymphomas in AIDS. Arch Pathol Lab Med, 1991, 115 : 115-120

KNOWLES DM, CHAMULAK GA, SUBAR M et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS) : the New-York University Medical Center experience with 105 patients (1981-1986). Ann Intern Med, 1988, 108 : 744-753.

SOLAL CELIGNY PH, BROUSSE N, REYES F et coll. Lymphomes non hodgkiniens, Paris, Frison-Roche, 1991.

GRIBBEN JG, FREEDMAN AS, NEUBERG D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med, 1991, 325 : 1525-1533

SOLAL CELIGNY PH, LEPAGE E, BROUSSE N et al. Recombinant interferon alpha-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med, 1993, 329 : 1608-1614

ARMITAGE JO. Therapy of non-Hodgkin’s lymphoma. N Engl J Med, 1993, 328 : 1023-1030

THE INTERNATIONAL NON-HODGKIN’S LYMPHOMA PRONOSTIC FACTOR PROJECT. A predictive model for aggressive non Hodgkin’s lymphoma. N Engl J Med, 1993, 329 : 987-994

LONGO DL, GLATSTEIN E, DUFFEY PJ et al. Treatment of localized aggressive lymphomas with combinate chemiotherapy followed by involved-field radiation therapy. J Clin Oncol, 1989, 7 : 1295-1302.

FISHER RI, GAYNOR ER, DAHLBERG S et al. Comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high grade non-Hodgkin’s lymphoma. N Engl J Med, 1993, 328 : 1002-1006.

COIFFIER B, GISSELBRECHT C, HERBRECHT R et al. LNH-84 regimen : a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol, 1989, 7 : 1018-1026

PHILIP T, ARMITAGE JO, SPITZER G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemiotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lyphoma. N Engl J Med, 1987, 316 : 1493-1498

Maladie de Hodkin

REYES F. Maladie de Hodgkin. In : J Breton-Gorius, F Reyes, H Rochant et coll. L’hématologie de Bernard Dreyfus, Paris, Flammarion Médecine-Sciences, 1992 : 947-968

D’AGAY MF, GAULARD PH. Histopathologie de la maladie de Hodgkin. In : J Breton-Gorius, F Reyes, H Rochant et coll. L’hématologie de Bernard Dreyfus, Paris, Flammarion Médecine-Sciences, 1992 : 968-973.

JARRETT RF. Hodgkin’s disease. In : AF Flemming. Epidemiology of haematological disease. Part I, Baillere’s Clin Hematol, 1992, 5 : 57-79

KELSEY KI, CAGGANA-AVILES M, MAUCH P et al. Mutagenesis after therapy for Hodgkin’s disease. In : JH Antin, LN Shulman. Therapy related second malignancies. Hematol/Oncol Clin North Am, 1993, 7 : 353-367

HENRY AMAR M, DIETRICH PY. Acute leukemia after the treatment of Hodgkin’s disease. In : JH Antin, LN Shulman. Therapy related second malignancies. Hematol/Oncol Clin North Am, 1993, 7 : 369-387

Chaînes lourdes

AUCOUTURIER P, KHAMLICHI AA, TOUCHARD G et al. Brief report : heavy chain deposition disease, N Engl J Med, 1993, 329 : 1389-1393

SELIGMANN M. Maladie des chaînes lourdes. In : J Breton-Gorius, F Reyes, H Rochant et coll. L’hématologie de Bernard Dreyfus, Paris, Flammarion Médecine-Sciences, 1992 : 1037-1052

L’hémoglobinurie paroxystique nocturne

Socié G, Mary JM, De Gramont A, Rio B, Leporrier M, Rose C, Heudier P, Rochant H, Cahn JY, Gluckman E. Paroxysmal nocturnal hemoglobinuria : long-term follow up and prognostic factors. Lancet 1996 ; 348 : 573-577

Socié G & Gluckman E. L’hémoglobinurie paroxystique nocturne.

Encyclopédie Médico Chirurgicale, 13-006-D-25,1997.

Myélome

COGNE M, SILVAIN C, KHAMLICHI AA. Structurally abnormal immunoglobulins in human immunoproliferative disorders. Blood, 1992, 79 : 2181-2195.

RAVAUX P, ROUX C. Os et myélome. Rev Prat, 1993, 43 : 293-297

LEGOAS F, MOUGENOT B, MIGNON F, RONCO P. Complications rénales tubulo-intersticielles du myélome. Rev Prat, 1993, 43 : 307-313

CHASSANDE B, LEGER JM. Manifestations neurologiques des gammapathies monoclonales. Rev Prat, 1993, 43 : 315-320

DELATTRE JY, SAID G. Neuropathies périphériques au cours des dysglobulinémies. Rev Prat, 1991, 41 : 1476-1481

BROUET JC. Traitement du myélome multiple. Rev Prat, 1993, 43 : 321-325

TROUSSARD X, LEPORRIER M. Place of double half body irradiation in the treatment of multiple myeloma. J Clin Oncol, 1991, 9 : 2233-2234

BATAILLE R, GRENIER J, SANY J. ß2-microglobulin in myeloma : optimal use for staging, prognosis and treatment. A prospective study of 160 patients. Blood, 1984, 63 : 468-476

Macroglobulinémie de Waldenström

LEPORRIER M. Signification d’une macroglobulinémie monoclonale. Rev Prat, 1993, 43 : 298-301

NYDEGGER UE, KAZATCHKINE MD, MIESCHER PA. Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins. Semin Hematol, 1991, 28 : 66-77.

RAUSCH PG, HERION JC. Pulmonary manifestations of Waldenström’s macroglobulinemia. Am J Hematol, 1980, 9 : 201-219

BRAWN LA, PARSONS MA, ALLAMBY P et al. Massive cardiac disease in a patient with Waldenström’s macroglobulinemia. J Clin Pathol, 1988, 41 : 475-478

CHASSANDE B, LEGER JM. Manifestations neurologiques des gammapathies monoclonales. Rev Prat, 1993, 43 : 314-316

BRADEN GL, MIKOLICH DJ, WHITE ICF et al. Syndrome of inappropriate antidiuresis in Waldenström’s macroglobulinemia. Am J Med, 1986, 80 : 1242-1244

GEHA RA, QUINI I, AUSTEN KF et al. Acquired C1-inhibitor defeciency associated with anti-idiotypic antibody to monoclonal immunoglobulins. N Engl J Med, 1985, 313 : 534-540

NYDEGGER UE, KAZATCHKINE MD, MIESCHER PA. Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins. Semin Hematol, 1991, 28 : 66-77

KYLE RA, GARTON JP. The spectrum of IgM monoclonal gammapathy in 430 cases. Mayo Clin Proc, 1987, 62 : 719-731

BUSSEL A. Indications des épurations plasmatiques au cours du traitement des macroglobulines monoclonales. Rev Prat, 1993, 43 : 326-329

Complications liées aux greffes d’organes et de moëlle osseuse

THEODORE J, STARNES VA, LEWISTON NJ. : Obliterative Bronchiolitis.Clinics in Chest Medicine 1990, 11, 309-321.

WRIGHT JL, CAGLE P, CHURG A, COLBY JV, MYERS J. : Diseases of the small airways. Am Rev Respir Dis 1992, 146, 240-262.

FOURNIER M, GROUSSARD O, SLEIMAN C, MAL H et coll. : Bronchiolite oblitérante après transplantation pulmonaire. Presse Med 1992, 21, 816-820.

YOUSSEM S.A, PARADIS IL, DAUBER JA, GRIFFITH BP. : Efficacy of transbronchial lung biopsy in the diagnosis of bronchiolitis obliterans in heart-lung transplant recipients. Transplantation 1989, 47 : 893-5

EPLER GR. : Bronchiolitis obliterans and airways obstruction associated with graft versus host disease. Clin Chest Med 1988, 9 : 551-6.

Rejet d’allogreffe

BENICHOU G, TAKIZAWA PA, o OLSON CA et al. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med, 1992, 175 : 305-308.

CHARPENTIER B. Mechanisme of rejection. Transplant Proc, 1983, 15 : 259-263.

KOURILSLKY P. CLAVERIE JM. MHC-antigen interaction : what does the T cell receptor see ? Adv Immunol, 1989, 45 : 107-193.

LARSEN CP, MORRIS PJ, AUSTYN JM. Migration of dendritic leukocytes from cardiac allograft into host spleens. J Exp Med, 1990, 171 : 307-314.

LECHLER Rl, LOMBARDI G. BATCHELOR JR et al. The molecular basis of alloreactivity. Immunoi Today, 1990, 11 : 83-88.

MATIS LA. The molecular basis of T-cell specificity. Ann Rev Immunol, 1990. 8:65-82.

PANINA-BORDIGNON P, CORRADIN G, ROOSNEK E et al. Recognition by class 11 alloreactive T cells of processed determinants from human serum proteins. Sciences, 1991, 252 : 1548-1550.

PLATT JL, LEBIEN TW, MIC CHAEL AK. Interstitial mononuclear cell population in renal graft rejection. Identification by monoclonal antibodies in tissue sections. J Exp Med, 1982, 155 : 17-30.

ROTZCHKE O, FALK K. Naturally occuring peptide antigens derived from the MHC class-I restricted processing pathway. Immunol Today, 1991, 12 : 447- 455.

VANDENSROEKE C, CAILLAT-ZUCMAN S, LEGENDRE C et al. Differential in situ expression of cytokines in renal allograft rejection. Transplantation, 1991, 51 : 602-609.

Traitements immunossuppresseurs

BAUMANN G, BOREL JF. Mecanismes moleculaires de l’action des agents immunosuppresseurs. Med Sci, 1992, 8 : 366-371.

CHAN GLC, PHARM D, CANAFAX DM, JOHNSON CA. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy, 1987, 7. 165-177.

CHRISTIANS U, SEWING KF. Cyclosporine metabolism in transplant patients. Pharmacol Ther, 1993, 57 : 291-345.

HRICIK DE, ALMAWI WY, STROM TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation, 1994, 57 : 979-989.

KAUFMAN DB, LONES J, MATAS AJ. New immunosuppressive agents : FK SO6, rapamycin, RS-61443, IS-deoxyspergualin. J Transplant, 1992, 2 : 20-27.

LEWIS R, PODBIELSKI J, SPRAYBERRY et al. Stability of renal allograft glomerular filtTation rate associated with long-term use of cyclosporine A. Transplantation, 1993, 55 : 1014-1017.

PETERS DH, FITTON A, PLOSKER GL, FAULDS D. Tacrolimus. A review of its pharmacology and therapeutic potentiel in hepatic and renal transplantation. Drugs, 1993, 46 : 746-794.

SKORECKI KL, RUTLI EDGE WP, SCHRIER RW. Acute cyclosporine nephrotoxicity. Prototype for a renal membrane signalling disorder. Kidney Int, 1992, 42 : 1-10.

TODD PA, BRWDEN RN. Muromonab CD3. A review of its pharmacology and therapeutic potentiel. Drugs, 1989, 37 : 871-899.

Prélèvement et conservation des organes

PALLIS C From braie death to braie stem death. Br Med 1, 1982, 285 : 1487-1490.

Romano P La mort cerebrale : definition et physiopathologie. In P Lang, D Houssin Le prelevement d’organes, Paris, Masson, 1992 : 33-42.

ROUGEMONT J, BARGE M, FRANKE J. Cerebral blood flow during increased subarachnoid pressure. Acta Neurochir, 1971, 25 : 19-36.